Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab vs Bevacizumab in Recurrent Glioblastoma
NCT02017717Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2014
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of nivolumab in glioblastoma (GBM), sponsored by Bristol Myers Squibb. Started Feb 2014; status: completed.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02017717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02017717.